Strogen® uno
Advanced BPH Treatment - Strogen® uno
Natural Sabal Palm Extract for Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS)
Manufactured by Strathmann GmbH & Co. KG, Germany
Distributed by BIOPHARMA PTE. LTD.
Product Name
Sabal Palm Fruit Extract Soft Capsule:
Sabal Palm Fruit Extract Soft Capsule
Sabal Palm Fruit Extract Soft Capsule (Strogen® uno):
Sabal Palm Fruit Extract Soft Capsule (Strogen® uno)
Active Ingredient
Standardized Sabal palm fruit extract (Sabal Serrulata)
Description / Appearance
Strogen® uno is a soft capsule containing a yellow-brown viscous liquid with a characteristic odor. Each capsule contains 0.42g of standardized Sabal Palm extract.
Indications / Therapeutic Uses
For urinary disorders caused by benign prostatic hyperplasia (BPH) stages I–II, including LUTS symptoms such as weak urinary stream, frequent urination, nocturia, and incomplete bladder emptying.
Specification
0.42 g × 120 capsules per box
Dosage and Administration
Oral use. Swallow with sufficient water after meals. Recommended dose: 1 capsule (0.42 g) once daily. The treatment course should be determined by a physician.
BPH Symptoms Treated
Frequent urination, nocturia, weak urine stream, difficulty starting urination, incomplete bladder emptying, urgency
Frequent Urination
Frequent daytime urination, needing to urinate more than 8 times per day
Nocturia
Need to wake up at night to urinate 2 or more times
Weak Urine Stream
Reduced urine flow force, prolonged urination time
Difficulty Starting Urination
Difficulty initiating urination, need to wait or strain
Incomplete Emptying
Feeling of incomplete bladder emptying after urination
Urgency
Sudden strong urge to urinate that's difficult to delay
Clinically Proven Efficacy
Multiple clinical studies confirm that Strogen® uno significantly improves IPSS scores, maximum flow rate (Qmax), and reduces LUTS symptoms in BPH patients.
BPH Symptoms Self-Assessment
Professional self-assessment tool based on International Prostate Symptom Score (IPSS)
Benign Prostatic Hyperplasia Self-Assessment
This assessment is based on the International Prostate Symptom Score (IPSS) to help you understand the severity of prostate-related symptoms. Results are for reference only, please consult a healthcare professional if needed.
Regulatory Information
Official authorization and compliance data
Marketing Authorization Holder
Strathmann GmbH & Co. KG
PU Number
8007668
Authorization Number
6764128.00.00
Authorization Date
March 29, 1999
Status
Authorized
Commercial Availability
Yes
Clinical Data
Evidence-based efficacy and safety profile for BPH treatment
BPH Treatment Efficacy
Clinical trials demonstrate significant improvement in urinary flow rate (Qmax) and reduction in residual urine volume in BPH patients. Studies show 65% improvement in International Prostate Symptom Score (IPSS) over 12 weeks of treatment.
Safety Profile
Well-tolerated with minimal adverse effects in BPH patients. Rare gastrointestinal discomfort (<2% of patients). No significant drug interactions reported in clinical studies.
Key Studies
Multi-center, double-blind, placebo-controlled studies involving 1,200+ BPH patients across European centers. Long-term safety data available for up to 3 years of continuous use.
Frequently Asked Questions
Learn more about BPH treatment with Strogen® uno
Order Strogen® uno Now
German OTC Herbal Extract - No Prescription Required
施通根® uno
Contact Us
Get in touch with our medical team for BPH treatment information
Company Address
9 Tampines Grande, Asia Green, #02-00, Singapore 528735